Saturday 17 October 2026
Export TLIS’s income statement to Excel — free account
Talis Biomedical Corporation
TLIS Healthcare Medical Devices
Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022. Operating cash flow growth for three consecutive years.
2.84
0.00
0.00%
Follow TLIS
| Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(9.10) | (5.14) | (1.58) | — | — | — | — |
P/S ratio |
6.85 | 2.75 | 11.09 | 5.39 | 5.39 | 5.39 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(15.72) | (5.97) | 3.74 | (0.59) | (12.69) | (35.24) | — |
Beneish M-Score |
(4.89) | — | 5.71 | (1.35) | — | — | — |
P/Operating CF |
(1.29) | (0.98) | (2.23) | (1.61) | (1.61) | (1.61) | — |
P/B ratio |
0.21 | 0.10 | 0.39 | 0.00 | 0.00 | 0.00 | — |
Price to Tangible BV |
0.21 | 0.10 | 0.39 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
(29.11) | (24.31) | (17.29) | (10.44) | (10.44) | (10.44) | — |
EV/EBITDA |
0.94 | 1.10 | 0.74 | 1.26 | 1.26 | 1.26 | — |
EV/Operating CF |
1.17 | 1.17 | 0.83 | 1.31 | 1.31 | 1.31 | — |
EV/FCF |
1.16 | 1.15 | 0.81 | 1.20 | 1.20 | 1.20 | — |
Quick Ratio |
8.75 | 10.30 | 12.18 | 10.83 | 5.80 | 2.64 | — |
Current Ratio |
8.86 | 10.52 | 12.36 | 11.77 | 5.97 | 2.77 | — |
Net Debt/EBITDA |
1.16 | 1.22 | 1.22 | 1.91 | 0.83 | 0.33 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.02 | 0.02 | 0.04 | 0.10 | 0.21 | 0.42 | — |
Operating CF/Net income |
0.86 | 0.89 | 0.89 | 0.95 | (0.92) | 0.98 | — |
Capex/Depreciation |
(0.63) | (0.18) | (1.82) | (10.75) | (0.80) | 0.00 | — |
Interest Coverage |
— | — | — | — | — | (460.86) | — |
| (63.32%) | (62.66%) | (306.27%) | 140.51% | (72.14%) | 58.34% | — | |
| (46.98%) | (51.95%) | (82.73%) | (81.32%) | 142.18% | (375.06%) | — | |
ROIC |
0.00% | 0.00% | (8,371.86%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(86.19%) | (91.20%) | (84.40%) | (50.12%) | 122.11% | (274.29%) | — |
Average Days of Receivables |
8.55 | 23.36 | 8.15 | 15.72 | 165.75 | 304.98 | — |
Research and Development Expense of Revenue |
1,906.94% | 1,471.97% | 1,923.48% | 813.85% | 598.74% | 769.37% | — |
Selling, General and Administrative Expense of Revenue |
1,322.12% | 846.40% | 517.73% | 119.79% | 172.59% | 200.21% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
203.89% | 111.55% | 112.38% | 33.67% | 24.26% | 0.00% | — |
Graham Net Nets |
3.57 | 6.86 | 2.25 | (2.01) | (2.01) | (2.01) | — |
Graham Number |
0.00 | 0.00 | 0.00 | 3,336.49 | 0.00 | 0.00 | — |
Earnings Yield |
(425.06%) | (864.88%) | (211.09%) | (154.52%) | (154.52%) | (154.52%) | — |
Free Cash Flow Yield |
(367.67%) | (768.92%) | (191.71%) | (161.50%) | (161.50%) | (161.50%) | — |
Revenue per Share |
1.17 | 2.67 | 5.42 | 77.36 | 77.52 | 0.67 | — |
Operating CF per Share |
(29.29) | (55.62) | (113.42) | (615.45) | (474.19) | (5.89) | — |
Capex per Share |
(0.27) | (0.90) | (1.90) | (58.00) | (11.27) | 0.00 | — |
Free Cash Flow per Share |
(29.56) | (56.52) | (115.31) | (673.44) | (485.46) | (5.89) | — |
Cash per Share |
42.22 | 72.31 | 153.89 | 1,224.42 | 421.13 | 1.94 | — |
Shareholders Equity per Share |
38.03 | 70.39 | 154.84 | (767.83) | (412.09) | 2.16 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
38.03 | 70.39 | 154.84 | (767.83) | (412.09) | 2.16 | — |
Free Cash Flow |
(53.73) | (101.75) | (174.25) | (95.22) | (24.90) | (20.94) | — |
Working Capital |
68.91 | 120.61 | 217.01 | 172.69 | 20.07 | 5.97 | — |
Capital Expenditures |
(0.49) | (1.61) | (2.87) | (8.20) | (0.58) | (0.53) | — |
Net Current Asset Value |
52.13 | 90.73 | 204.26 | (118.25) | (22.77) | 5.65 | — |
EV/EBIT |
0.93 | 1.02 | 0.74 | 1.25 | 1.25 | 1.25 | — |
Capex to Sales |
0.23 | 0.34 | 0.35 | 0.75 | 0.15 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||
Depreciation/Fixed assets |
0.25 | 2.67 | 0.15 | 0.08 | 0.47 | 0.36 | — |
Cash ROIC |
(36.84%) | (39.60%) | (37.35%) | (147.49%) | (5,367.24%) | (143.55%) | — |
Accounts Receivable Turnover |
11.92 | 19.60 | 25.06 | 9.61 | 2.09 | 1.26 | — |
Accounts Payable Turnover |
0.02 | 1.89 | 0.52 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
11,920.37 | 163.90 | 713.29 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
0.18 | 0.25 | 0.33 | 1.14 | 1.90 | 1.90 | — |
Average Payables |
2.55 | 4.45 | 5.01 | 3.24 | 1.54 | 1.54 | — |
Average Assets |
131.98 | 217.56 | 232.12 | 112.07 | 18.56 | 5.69 | — |
Average Common Equity |
97.92 | 180.36 | 62.70 | (64.86) | (36.57) | (36.57) | — |
Columns are period end dates